Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

塞库金单抗 医学 银屑病性关节炎 依那西普 安慰剂 银屑病 银屑病面积及严重程度指数 相伴的 随机对照试验 内科学 皮肤病科 胃肠病学 肿瘤坏死因子α 病理 替代医学
作者
Alice B. Gottlieb,Richard Langley,Sandra Philipp,Bárður Sigurgeirsson,Andrew Blauvelt,Ruvie Martin,C. Papavassilis,Shephard Mpofu
出处
期刊:PubMed 卷期号:14 (8): 821-33 被引量:49
链接
标识
摘要

Interleukin (IL)-17A is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, secukinumab, a fully human anti-IL-17A monoclonal antibody, demonstrated robust efficacy in psoriasis, with rapid onset, high response rates, and durable response.To evaluate the efficacy of secukinumab in subjects with psoriasis and concomitant psoriatic arthritis (PsA) with respect to psoriasis symptoms and physical function, we conducted pre-specified subanalyses of the phase 3 FIXTURE and ERASURE trials.The 52-week FIXTURE and ERASURE trials randomized subjects with moderate-to-severe plaque psoriasis to subcutaneous secukinumab 300 or 150 mg (Baseline, weeks 1, 2, 3, every 4 weeks from week 4 until week 48), etanercept 50 mg (twice weekly through week 12, once weekly thereafter through week 51; FIXTURE only), or placebo. In this analysis, changes in Health Assessment Questionnaire-Disability Index (HAQ-DI) and PASI 75 responses were assessed in subpopulations with concomitant PsA (n=196, FIXTURE; n=171, ERASURE).Physical functioning (mean change from Baseline in HAQ-DI) was greater with secukinumab 300 mg vs. placebo at week 12 in both trials (FIXTURE, -0.41 vs. 0.02/P=0.0001; ERASURE, -0.35 vs. -0.08/P=0.0003); corresponding values were -0.29 for etanercept and -0.19 for secukinumab 150 mg in FIXTURE and -0.18 for secukinumab 150 mg in ERASURE. Greater responses were seen in subjects with greater Baseline disability (HAQ-DI ≥05). Week 12 PASI 75 responses were higher with secukinumab 300 mg/150 mg vs. placebo in FIXTURE (72%/59% vs. 2%) and ERASURE (68%/70% vs. 4%; all P<0.0001) and with secukinumab 300 mg vs. etanercept (72% vs 39%; P=0.0084).Secukinumab 300 mg produced significant improvement in psoriasis and physical functioning in subjects with concomitant PsA. ClinicalTrials.gov numbers: NCT01358578 (FIXTURE); NCT01365455 (ERASURE)

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
毛豆爸爸应助Tomice采纳,获得150
1秒前
慕青应助格子布采纳,获得10
2秒前
爱笑的无心完成签到 ,获得积分10
3秒前
shw发布了新的文献求助30
3秒前
x1完成签到,获得积分10
3秒前
英俊的铭应助pophoo采纳,获得10
4秒前
刘莅完成签到 ,获得积分10
5秒前
一杯完成签到,获得积分10
6秒前
lyjj023发布了新的文献求助30
6秒前
21完成签到,获得积分10
8秒前
8秒前
阿莫西林完成签到,获得积分10
10秒前
10秒前
11秒前
12秒前
14秒前
klp335完成签到,获得积分10
14秒前
x1发布了新的文献求助10
14秒前
15秒前
格子布发布了新的文献求助10
15秒前
郑绒绒完成签到 ,获得积分10
16秒前
yjchenf完成签到 ,获得积分10
17秒前
17秒前
顾矜应助王4采纳,获得10
18秒前
20秒前
ylc发布了新的文献求助10
21秒前
lyjj023发布了新的文献求助10
21秒前
幸福语儿发布了新的文献求助30
21秒前
畅快幻柏发布了新的文献求助20
22秒前
太阳完成签到,获得积分10
23秒前
26秒前
27秒前
27秒前
Akim应助格子布采纳,获得10
27秒前
深情安青应助怕黑月光采纳,获得10
28秒前
碘伏完成签到 ,获得积分10
28秒前
29秒前
12345678完成签到,获得积分10
29秒前
31秒前
畅快幻柏完成签到,获得积分20
33秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141401
求助须知:如何正确求助?哪些是违规求助? 2792423
关于积分的说明 7802495
捐赠科研通 2448598
什么是DOI,文献DOI怎么找? 1302633
科研通“疑难数据库(出版商)”最低求助积分说明 626650
版权声明 601237